BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.20 USD
-0.24 (-3.23%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $7.18 -0.02 (-0.28%) 4:38 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.20 USD
-0.24 (-3.23%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $7.18 -0.02 (-0.28%) 4:38 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Zacks News
BioCryst (BCRX) Upgraded to Buy: Here's Why
by Zacks Equity Research
BioCryst (BCRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for BioCryst (BCRX) points to a 99.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of 68.42% and 11.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst (BCRX) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 92.6% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 11.43% and 2,905.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of -16.67% and 4.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
by Zacks Equity Research
Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.
BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?
by Zacks Equity Research
BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
by Zacks Equity Research
Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%.
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of 4% and 0.62%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think BioCryst (BCRX) Could Surge 107.2%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 107.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Strength Seen in Marinus Pharmaceuticals (MRNS): Can Its 5.4% Jump Turn into More Strength?
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ImmunoGen (IMGN) delivered earnings and revenue surprises of 36% and 129.21%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of -100% and 6.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for BioCryst (BCRX)
by Zacks Equity Research
BioCryst (BCRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.